Anti-apoptotic protein Lifeguard does not act as a tumor marker in breast cancer

The aim of the present study was to use an enzyme-linked immunosorbent assay (ELISA) to determine the concentrations of Lifeguard (LFG) protein in the serum of 36 patients diagnosed with breast cancer and to compare these values with the concentrations of LFG protein in the serum of 7 healthy volunt...

Full description

Saved in:
Bibliographic Details
Published inOncology letters Vol. 13; no. 3; pp. 1518 - 1524
Main Authors Maurer, Viktor, Reimers, Kerstin, Lück, Hans J, Vogt, Peter M, Bucan, Vesna
Format Journal Article
LanguageEnglish
Published Greece Spandidos Publications 01.03.2017
Spandidos Publications UK Ltd
D.A. Spandidos
Subjects
Accounting
Apoptosis
Breast cancer
Care and treatment
Development and progression
Gene expression
Genetic aspects
Health aspects
Kinases
Oncology
Patients
Proteins
Standard deviation
Tumor proteins
Tumors
United States > US
Germany
tumor marker
breast cancer
Lifeguard
Online AccessGet full text

Cover

More Information
Summary:The aim of the present study was to use an enzyme-linked immunosorbent assay (ELISA) to determine the concentrations of Lifeguard (LFG) protein in the serum of 36 patients diagnosed with breast cancer and to compare these values with the concentrations of LFG protein in the serum of 7 healthy volunteers in order to detect a possible association between the expression of LFG in the serum and the degree of malignancy of the disease. Although there is no direct association between the LFG protein concentration in the serum and the degree of malignancy of breast cancer, a statistically significant distribution of the concentration in all investigated samples was observed. This indicated an association between the LFG protein concentration in human serum with a currently unknown factor.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2017.5658